The appointment of Scott R. Ward, with his extensive experience in the medical technology field, is likely to be viewed positively by investors. His previous role as CEO of Cardiovascular Systems, which was acquired by Abbott, suggests he brings valuable expertise and leadership to InspireMD. This could enhance the company's strategic direction and execution, potentially leading to positive investor sentiment and a short-term increase in stock price.